Skip to main content
BDTX $1.32 -4.69%
BDTX logo
BDTX · Black Diamond Therapeutics, Inc.
Track BDTX — free
$1.32 -0.07 (-4.69%)
Market Cap
$75.28M
Shares
57.47M
Volume · Nov 20 662.46K Avg daily vol (3M) 697.63K
All webcasts

Conference · 2026-11-19

Black Diamond Therapeutics, Inc. (BDTX) November 19, 2026 Conference Transcript

Concluded Nov 19, 2026 Audio replay
Nov 19, 2026 23:40 42 turns
Period
2026-11-19
Runtime
23:40
Sources
2 artifacts

Transcript & audio

23:40 Audio
Farzin Hak Analyst — Jefferies

Okay. Good morning, everyone. My name is Farzin Hak, one of the biotech analysts at Jefferies. It's my pleasure to introduce Mark Valleca, CEO of Black Diamond Therapeutics. Thank you for joining us today. Maybe to start off with a quick overview of the company, and then we can dig into the very specific eventful week we had last week on the clinical and regulatory update.

Sure. Good morning, everyone. Real pleasure to be with you in London, and welcome to those joining who are listening in. Black Diamond is a clinical stage oncology company. We're entirely focused on advancing our lead program, which is Silovertinib, which we believe is a best and potentially first-in-class, fourth-gen, EGFR-TKI. And, yes, Farzan, we did have an eventful week. Last week, we disclosed some exciting new data, as well as the outcome of a very collaborative end-of-phase-two meeting with the FDA, where we got very clear guidance on a path to accelerated approval. So, look forward to talking more about that with you and everyone.

Farzin Hak Analyst — Jefferies

Maybe to start off, like, how large is the U.S. opportunity in the non-classical EGFR mutant setting? Like, and what proportion of those patients have brain mist? It's not in each setting, like the ROS1, but any color would be helpful.

Yeah, there are about 10,000 patients every year in the United States who present with one of these non-classical mutations, sometimes called atypical mutations. And these are essentially all mutations outside of the classical mutations, exon-19-DEL, L858R, and exon-20 insertions. And almost half of those patients actually present with brain metastases. And what we're learning is, you know, patients who are treated with afatinib and osomertinib, which are really the only therapies that are used in that setting, have very poor outcomes with median PFS in the five- to six-month range. So substantial opportunity, almost half the patients present with brain metastases and very poor outcomes with existing therapies.

Farzin Hak Analyst — Jefferies

One thing that may be underappreciated is the breadth of the capabilities. So cilivertinib is being developed across essentially the full spectrum, whereas Oric is focused more on the PAC and then L861X. And then you have the Ariven, pharma drug, which basically focuses on the PAC. So how much larger does that make the address of the population for cilivertinib?

Yeah, it's much larger, and it's commercially meaningful. So the non-classical group is comprised of over 50 unique oncogenic mutations. Some of those, about half, fall into the pack category, right? And you're right, both OREC and Arrivine are focused on that pack category. We're focused on the full spectrum. We have demonstrated clinical responses, radiographic responses, in more than 20 of those mutations. And this was a key part of our FDA discussion because they accepted our definition of non-classicals, which is quite simple. If you don't have a classical mutation or an exon 20 insertion, You are eligible for our drug. So that's commercially meaningful. It's double the size of where enozertinib and firmonertinib could go. But for a physician, a prescribing physician who gets an NGS report, most often sees a classical mutation and knows what to prescribe. It's osomertinib. But very often, about a quarter of cases, that second page lists one of these non-classical mutations. Now it's very clear what they can give. They don't have to parse the alphabet soup of PAC, L861X. It's just very clear. So that was a big win, one of the big wins in our FDA conversation.

Farzin Hak Analyst — Jefferies

Makes sense. And then you've got alignment on the phase three, so there's like 300 patients with brain meds and uses the CNS ORR by Rano-BM. The FDA was very supportive.

I've been in front of them many times in my career, one of the most collaborative meetings I've been in. It's very clear they want to help us get this drug to patients as fast as possible. And that's because, you know, we went to them with a data set of over 200 patients in our phase one, phase two study, most of those with non-small cell lung cancer and, of course, the phase two data set in the front line setting. If you think about our competitors, they went with much smaller data sets, mostly from Asia. All of our patients were primarily in the U.S., a few sites in Canada. So very robust data package. And you mentioned CNS activity that we believe is truly best in class. So 86% CNS ORR by Rayno BM. The most stringent criteria, and the only one accepted by FDA per their guidance for assessing brain metastases, Rayno-BM versus Resist. So we're at 86%, FIRMO's at 28%, and ORIC, depending on how you look at their denominator, is anywhere from 50% to 57%. And, you know, those competitors, as you mentioned, have to win on systemic ORR. It's going to be very challenging because, you know, the benchmark for a fatinib is 66%. The benchmark for CNSORR, where the fatinib and osimertinib, is in the mid-30s, and we're at 86%. Again, what's very clear in this patient population is you need to control. Brain metastases. ORR, systemic ORR, is a poor predictor of PFS. It's a poor predictor of PFS. You have to control brain metastases. If you win in the brain, you win everywhere. And that's why the FDA actually encouraged us to use CNS ORR as the endpoint for accelerated approval. The studies, I think we'll get to this, adequately powered. And then for full approval, It's just, as you typically see in frontline lung cancer, PFS. We only need to be similar on systemic ORR. That's a big win.

Farzin Hak Analyst — Jefferies

Makes sense. And then you have guided to 18 months of enrollment from a 2Q-2027 start, and the CNS-ORR top line is in 2029. But does the trial need to be fully enrolled before you can cut the CNS-ORR, or has FDA agreed to minimum number of evaluable patients and follow-ups so that that could support an earlier analysis?

Yes. So we actually, you know, the first part of the discussion was about patient population. The second part was about endpoints, and then we really worked collaboratively with them on study design, including size of the trial, power estimates, and timing of endpoints and what kind of follow-up they needed. So, I mean, this trial has the blessing of the agency, and to answer your question, we do expect to cut the data about the time that the trial is fully enrolled, which is about 18 months, so think, you know, end of 28. At that time, there should be enough patients with sufficient follow-up to assess CNSORR rigorously and spend a small amount of alpha to compare it to the control arm, which is the fatinib and osomertinib. Most of the alpha will be for the full approval endpoint, PFS. Remember, we don't have to spend any alpha on systemic ORR. We just need to show similarity and just show no detriment to OS.

Farzin Hak Analyst — Jefferies

Great. And then in terms of timeline, AriVent has started the registration study, I think it was in December 2025, and they have like 480 patients, so much larger. OREC plans to start in first half 27. Does your smaller 300-patient study and the CNS ORR potentially give you a realistic bet to beat both competitors?

We're confident we can beat both, and here's why. Both OREC and AriVent need to win on systemic ORR to get accelerated approval. The comparator in both of their trials is Afatinib, also Osimertinib. Afatinib is at 66% ORR. The systemic ORR disclosed by both OREC and ORIVANT are high 60s, low 70s. You need to run a very large trial to detect, statistically, a difference in systemic ORR. We're at 86% CNS ORR, mid-30s published data for afatinib and osimertinib. So very clear that we have an opportunity for accelerated approval based on CNS ORR, And therefore, could leapfrog and get onto the market sooner and be the first in class fourth gen.

Farzin Hak Analyst — Jefferies

And then you have the control arm. Like, what do you expect to get the share of the split between the osimertinib and afritinibary region? Like, is the split stratified, capped, or because OSI has some CNS activity?

Yeah, OSI does have some CNS activity, but I'd urge anyone who wants to dive into this more to look at a very recent publication, a large study out of Memorial Sloan-Kettering, nearly 500 patients that were studied on osimertinib, And these patients all had brain metastases. About 45 had atypical or non-classical mutations. The rest had either exon 19 DEL or L858R. The reason I raise this is, you know, the outcomes in those patients is quite poor. This is where we get the five months of PFS for osimertinib. It's not very good for L858R patients either, nine to ten months PFS, which is potentially an opportunity for us. To answer your question about, you know, OC versus afatinib. It will be based on region. It's not capped. We don't have a pre-specified number in mind. It will be specified by region. And, you know, Afatinib is widely used in Asia, some countries in Western Europe, certainly Eastern Europe, Canada, countries in South America, Mexico. OC definitely primarily used in the U.S., and we'll have the same sites that we've been using in the U.S. So we would expect about 40-ish percent of patients to be on osomertinib and 60 percent on the control arm to be on afatinib, just based on region.

Farzin Hak Analyst — Jefferies

And afatinib is actually approved on three of the non-classical mutations, the PAC ones. So how will your broad mutational coverage complicate matters for the control arm? Like, how do you make sure that they're specifically stratified?

Yeah, it's true. Per label, afatinib, just the three mutations are listed, right, the 2-PAC and L861Q. Similar for osomertinib's NCCN guidelines, it's the same three mutations. However, in practice, both of those drugs are used for all of these atypical or non-classical mutations. So it should not be a problem. We've talked to all of the key investigators for this study across the globe. We're very busy at ESMO talking to folks who will be enrolling in this study. And they know that these are the drugs, these are really the only drugs that they can use in this setting. There's a very low usage of amivatinib plus lisertinib.

Farzin Hak Analyst — Jefferies

And then to get your phase three started, FDA wanted the 150-meg running cohort with the cohort four, and before that, phase three opened. So while FDA didn't specify a minimum data set, how many of the planned 20 patients do you expect to have treated, and how much follow-up do you need before you can get back to the FDA?

Yeah. So let's be clear. We went again with a mountain of exposure response data from over 200 patients. FDA completely understood our rationale for starting at 150 milligrams, and we have been enrolling patients at 150 milligrams since August, so we went into the meeting with that cohort already under our belt and said, look, we want to start at 150. Here's our rationale. We should see better safety without compromising efficacy. They said, we got it. We understand. All your exposure response analysis makes sense. Just bring a sufficient number of patients with safety data only. And we probed and said, you know, what kind of safety data? Primarily interested in seeing a decrease in the rate of dose reductions. So we're currently at about 80% of patients needing a dose reduction. They'd like to see something in the 60% range. Now, we're dosing these patients now. Those dose reductions happen within the first month. We are very confident we'll be able to demonstrate. A decrease in the rate of dose reductions, and I think we'll talk about the AE profile in a minute, but, you know, those AEs, which are all just EGFR-mediated, come down significantly on dose reduction, and our median dose intensity in the study, the 43-patient study, frontline study, was 126 milligrams. Much closer to 150 than 200. So, again, FDA understands that we can dose-reduce without compromising efficacy. We've never lost a response on a dose-reduced patient.

Farzin Hak Analyst — Jefferies

So 60% is what FDA specified, and you're running ahead of it?

It wasn't specified. They said, you'll know. Bring us, when you have enough patients, showing a significant reduction in dose reductions. And we said, you know, something like 60%. They said, you'll know. Okay. And they were, again, very collaborative. We don't have to have a formal meeting with them. It's just you can put it in with the protocol. So that's what we will aim to do. It will not impede FBI. Which we're targeting in the second quarter of next year.

Farzin Hak Analyst — Jefferies

So coming back to the timing, like, can you file the IND and begin site startup activities before you get that cohort 4 data?

Yes. We are in full ramp-up mode now for the phase 3. So we're doing this in parallel. We'll, again, likely submit the protocol with that updated safety data from cohort 4. Get the blessing of the FDA that, yes, you've checked the box. You've shown that the tolerability profile is better. The rate of dose reductions is less, and then we can proceed.

Farzin Hak Analyst — Jefferies

So the IND filing will be at that time? And then you have the 80-patient cohort without brain meds to be included as supported efficacy. But is it purely intended for compendia, or can it potentially get on the label?

You don't have that discussion with the FDA now. You wait for data. You know, most of the conversation was focused on the randomized study, again, adequate powering in size. That is a single-arm cohort. It's meant for kind of operational efficiencies. If you have a non-classical mutation, you're in the trial. If you have brain mets, you're in the randomized portion. If you don't, you're in the single-arm cohort. The PFS that we have in that patient population is 23.5 months, 24 patients. Not a single one of them has developed a brain metastasis, and we've been following them for almost a year and a half. That's remarkable when you think about osomertinib and afatinib that have 70% to 80% of their patients progressing in the brain. So I think you bring the data to the agency. At a minimum, I think it'll get us a compendia listing in NCCN, which means reimbursement in this country, wide usage. It'll get incorporated into the EMR. Whether it winds up in the label is up to negotiation, but it was designed to answer your question simply as primarily as a compendia study.

Farzin Hak Analyst — Jefferies

And osimertinib is a similar path.

Yeah, Osimertinib is, the reason it's widely prescribed in this patient population now is it is in the NCCN guidelines, so it is the go-to option in the U.S. for patients with atypical mutations.

Farzin Hak Analyst — Jefferies

You also have the leptomeningeal cohort. That's like 20 patients, small ones. Was that – did FDA specifically request that, or what is the strategy with that?

They didn't request it. They actually suggested it. They said, look, this is a highly CNS-active EGFR-TKI. I think it's the most highly active they've seen, though they would never say that. And they said, you know, patients with leptomeningeal disease have the highest unmet medical need, Very poor outcomes, two, three-month PFS with existing therapies. You should run a small cohort, and we agree, so we're going to.

Farzin Hak Analyst — Jefferies

Coming back to the AE profile, so rash, diarrhea, abstemia diarrhea, they're all consistent with on-target EGFR inhibition. So how does the safety tolerability profile compare to the approved third-generation TKIs, and do you see potential for silovertinib to offer a better quality of life, basically, in the front-line settings?

Yeah, I mean, patients in the front-line setting want... Oral therapy. Again, the uptake of ribavent, whether it's classical mutations or atypicals, is very low because of that fact. Our rate of grade 3AEs after dose reduction is almost identical to osomertinib, and we're confident that when we start at 150, it will also be. And they are all on target. We do not have any off-target AEs, no QTC prolongation, no LFT elevations. It's just primarily rash and diarrhea, which are well-managed. We've been working with EGFR-TKs for 20 years. Docs know how to treat those.

Farzin Hak Analyst — Jefferies

Actually, Aussie and Flora 3, Flora, they actually had grade 3s of 34%. Over 30%, exactly.

So, you know, we're well within that range after dose reduction, which we expect we'll see when we start at 150.

Farzin Hak Analyst — Jefferies

Got it. And then I want to touch on the GBM aspect as well, because that's something also differentiated, and you get a little credit for it right now. So the randomized phase 2, it compares the celebertonib with the timozolamide. And then, so PFS is the primary endpoint, and then you should get some data in 1st of 28. So what is the hazard ratio or the month in delta, basically, like for the interim to convert to a potential registrational study?

Yeah, so I think we all know GBM is the area of highest unmet medical need in oncology. Most patients are not alive two years after a diagnosis. There are no good therapies other than temozolomide, which was approved 21 years ago. So we're combining silovertinib with temozolomide versus temozolomide alone, the reason being half of these patients have an EGFR alteration that is potently inhibited by silovertinib, and silovertinib has best-in-class brain penetrance. We've shown it in measured drug levels directly in tumors treated with silovertinib. It is the first EGFR TKI to couple both broad-spectrum coverage of EGFR alter agency and in glioblastoma and high brain penetrance. So we definitely think this is worth doing. We've completed the safety run-in. Not surprisingly, the dose is 150. We're randomizing 75 patients, silovertinib plus temozomide versus 75. To answer your question. If the PFS signal, interim PFS, which will come in the first half of 28, is lower than, let's call it 0.6 to 0.65, we will convert that trial to an OS trial, and it will be registrational. So that is a big deal. You're talking about the first potential therapy approved in glioblastoma in 21 years. That is a 7,000 patient in the U.S. population every year with no good options.

Farzin Hak Analyst — Jefferies

Great. And then you also talked about potentially partnering on moving the assets into Phase 3. So what is the current status? And has the recent clinical and FDA progress changed either the level of inbound interest or your leverage in these discussions?

First, like, what are we looking for in a partner? We want to get this drug to as many patients as possible. We think it's, again, best, potentially first-in-class fourth gen EGFR TKI, so if a partner can help us do that and preserve shareholder value, we'll do that. No question, and I probably can't comment anymore, our disclosure last week has substantially increased inbound interest on this program.

Farzin Hak Analyst — Jefferies

Okay. So what is the cash position and runway now, and then the key catalyst that investors should focus in the next 12 months?

So we just disclosed in the same release last week, ended the third quarter with $102 million. That's sufficient to fund the company until the second half of 2028. So it funds through... The GBM readout that we talked about. It funds through cohort four reading out, which will be next year. That's the 150-minute cohort, FPI for the phase three. And, you know, those open-label cohorts, the non-brain mets and the lepta-meningeal, those are single-arm open-label. And in, you know, 2028, you know, we can look at, let's say, landmark PFS data from those. The big endpoint, obviously, is CNSORR in 2029.

Farzin Hak Analyst — Jefferies

So if you're sitting here a year from now, and the celebrity story has played out the way you expect it to be, so what do you think investors will wish they had understood about the black diamond today?

That this is truly the best and first generation, I'm sorry, best in class and first in class, fourth gen EGFRTKI. It's not a niche drug. We can get it on the market quickly by addressing a very targeted patient population. But what we've learned about EGFR mutant non-small cell lung cancer is these patients progress in the brain. The Meow It All paper, JTO, October, read it. It tells you that there is significant unmet medical need in patients treated with a $10 billion drug, Tigriso. So you get non-classical mutations. What about adjuvant use? What about L858R patients where Tegresso does not have a survival advantage? This could be a very big drug.

Farzin Hak Analyst — Jefferies

Thank you so much. Always great talking to you.

Thank you. Thank you, Farzan.

Analyst Q&A · 1 question
Full-screen source Call document